Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keeping Track of Genzyme

Executive Summary

Genzyme is that rare biotech company that is both profitable and diversified. To finance its entrepreneurial businesses without diluting its original shareholders, it has issued separate "tracking" stocks for its various wholly-owned divisions: Tissue Repair, Molecular Oncology, and its General division. The financing strategy brings tax advantages and a way to incentivize managers. But skeptics worry that it adds a complexity that will scare off investors.
Advertisement

Related Content

Why Doesn't Pharma Get Smaller?
Why Doesn't Pharma Get Smaller?
Genzyme: Why Diversification is Starting to Look Smart
Genzyme: Why Diversification is Starting to Look Smart
Genzyme Buys a Bigger Presence in Oncology

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV000776

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel